Esketamine - Johnson & Johnson

Drug Profile

Esketamine - Johnson & Johnson

Alternative Names: JNJ-54135419; S-ketamine

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Major depressive disorder

Most Recent Events

  • 09 Apr 2018 Janssen suspends a phase II trial in Major depressive disorder (Adjunctive treatment, In adolescents, In children) in Spain, Hungary, Poland, France, Bulgaria, Brazil, Belgium, USA, Italy for new subject recruitment due interruption in clinical supplies(Intranasal) (NCT03185819)
  • 15 Feb 2018 Janssen Research & Development plans a phase III trial for Major depressive disorder (Treatment-resistant) (Combination therapy) in China (NCT03434041)
  • 02 Feb 2018 Janssen Research and Development completes a phase-I trial for Renal failure in USA (Intranasal) (NCT02606084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top